High-dimensional biology to comprehend hepatocellular carcinoma

References

• Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin. Liver Dis.19, 271–285 (1999).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362, 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet.31, 339–346 (2002).
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States, a population based case control study. Gut54, 533–539 (2005).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma, Chemoembolization improves survival. Hepatology37, 429–442 (2003).
   PubMed Web of Science ®Google Scholar
• Chang MH, Shau WY, Chen CJ et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA284, 3040–3042 (2000).
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma, recent trends in the United States. Gastroenterology127, S27–S34 (2004).
   PubMed Web of Science ®Google Scholar
• Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet351, 214–215 (1998).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis, incidence and risk factors. Gastroenterology127, S35–S50 (2004).
   PubMed Web of Science ®Google Scholar
• Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis.27, 55–76 (2007).
   PubMed Web of Science ®Google Scholar
• Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J. Gastroenterol. Hepatol.21, 15–21 (2006).
   PubMed Web of Science ®Google Scholar
• Kallioniemi A, Kallioniemi OP, Sudar D et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science258, 818–821 (1992).
   PubMed Web of Science ®Google Scholar
• Sy SM, Wong N, Lai PB, To KF, Johnson PJ. Regional over-representations on chromosomes 1q, 3q and 7q in the progression of hepatitis B virus-related hepatocellular carcinoma. Mod. Pathol.18, 686–692 (2005).
   PubMed Web of Science ®Google Scholar
• Katoh H, Shibata T, Kokubu A et al. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization, identification of genetic indicators to predict patient outcome. J. Hepatol.43, 863–874 (2005).
   PubMed Web of Science ®Google Scholar
• Guan XY, Fang Y, Sham JS et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer29,110–116 (2000).
   PubMed Web of Science ®Google Scholar
• Pang A, Ng IO, Fan ST, Kwong YL. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet. Cytogenet.146, 8–15 (2003).
   PubMedGoogle Scholar
• Wong N, Lai P, Lee SW et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis, relationship to disease stage, tumor size, and cirrhosis. Am. J. Pathol.154, 37–43 (1999).
   PubMed Web of Science ®Google Scholar
• Bentz M, Plesch A, Stilgenbauer S, Dohner H, Lichter P. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer21, 172–175 (1998).
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Mori N, Tamesa T et al. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod. Pathol.17, 617–622 (2004).
   PubMed Web of Science ®Google Scholar
• Midorikawa Y, Yamamoto S, Ishikawa S et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene25, 5581–5590 (2006).
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Komura D, Tsuji S et al. Allelic dosage analysis with genotyping microarrays. Biochem. Biophys. Res. Commun.333, 1309–1314 (2005).
   PubMed Web of Science ®Google Scholar
• Kato N, Ji G, Wang Y et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology42, 846–853 (2005).
   PubMed Web of Science ®Google Scholar
• Torbenson M, Kannangai R, Abraham S et al. Concurrent evaluation of p53, β-catenin, and a-fetoprotein expression in human hepatocellular carcinoma. Am. J. Clin. Pathol.122, 377–382 (2004).
   PubMed Web of Science ®Google Scholar
• Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science257, 967–971 (1992).
   PubMed Web of Science ®Google Scholar
• Diatchenko L, Lau YF, Campbell AP et al. Suppression subtractive hybridization, a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc. Natl Acad. Sci. USA93, 6025–6030 (1996).
   PubMed Web of Science ®Google Scholar
• Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science259, 946–951 (1993).
   PubMed Web of Science ®Google Scholar
• Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science270, 467–470 (1995).
   PubMed Web of Science ®Google Scholar
• Lockhart DJ, Dong H, Byrne MC et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol.14, 1675–1680 (1996).
   PubMed Web of Science ®Google Scholar
• Brazma A, Hinqamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME) – toward standards for microarray data. Nat. Genet.29, 365–371.
   PubMed Web of Science ®Google Scholar
• Xu XR, Huang J, Xu ZG et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc. Natl Acad. Sci. USA98, 15089–15094 (2001).
   PubMed Web of Science ®Google Scholar
• Midorikawa Y, Makuuchi M, Tang W, Aburatani H. Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J. Gastroenterol.13, 1487–1492 (2007).
   PubMed Web of Science ®Google Scholar
• Smith MW, Yue ZN, Korth MJ et al. Hepatitis C virus and liver disease, global transcriptional profiling and identification of potential markers. Hepatology38, 1458–1467 (2003).
   PubMed Web of Science ®Google Scholar
• Segal E, Sirlin CB, Ooi C et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat. Biotechnol.25, 675–680 (2007).
   PubMed Web of Science ®Google Scholar
• Bird A. Perceptions of epigenetics. Nature447, 396–398 (2007).
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs, small RNAs with a big role in gene regulation. Nat. Rev. Genet.5, 522–531 (2004).
   PubMed Web of Science ®Google Scholar
• Miska EA. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev.5, 563–568 (2005).
   Google Scholar
• Zamore PD, Haley B. Ribo-gnome, the big world of small RNAs. Science309, 1519–1524 (2005).
   PubMed Web of Science ®Google Scholar
• Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol.163, 1101–1107 (2003).
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology16, 394–400 (1999).
   Google Scholar
• Kanai Y, Ushijima S, Hui AM et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer71, 355–359 (1997).
   PubMed Web of Science ®Google Scholar
• Yamada S, Nomoto S, Fujii T et al. Frequent promoter methylation of M-cadherin in hepatocellular carcinoma is associated with poor prognosis. Anticancer Res.27, 2269–2274 (2007).
   PubMed Web of Science ®Google Scholar
• Wong CM, Ng YL, Lee JM et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology45, 1129–1138 (2007).
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang YL, Teng XM et al. Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer7, 126 (2007).
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Ladu S, Gorden A et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest.117, 2713–2722 (2007).
   PubMed Web of Science ®Google Scholar
• Oh BK, Kim H, Park HJ et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int. J. Mol. Med.20, 65–73 (2007).
   PubMed Web of Science ®Google Scholar
• Kondo Y, Shen L, Suzuki S et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res.37, 974–983 (2007).
   PubMed Web of Science ®Google Scholar
• Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene25, 2537–2545 (2006).
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology133, 647–658 (2007).
   PubMed Web of Science ®Google Scholar
• Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology43, S145–S150. (2006).
   PubMed Web of Science ®Google Scholar
• Xu L, Geman D, Winslow RL. Large-scale integration of cancer microarray data identifies a robust common cancer signature. BMC Bioinformatics8, 275 (2007).
   PubMed Web of Science ®Google Scholar
• Kimura M. Evolutionary rate at the molecular level. Nature217, 624–626 (1968).
   PubMed Web of Science ®Google Scholar
• King JL, Jukes TH. Non-Darwinian evolution. Science164, 788–798 (1969).
   PubMed Web of Science ®Google Scholar
• Kaposi-Novak P, Lee JS, Gomez-Quiroz L et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest.116, 1582–1595 (2006).
   PubMed Web of Science ®Google Scholar
• Su WH, Chao CC, Yeh SH et al. OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucl. Acids Res.35, D727–D731 (2007).
   Google Scholar
• Stock P, Monga D, Tan X et al. Platelet-derived growth factor receptor-a: a novel therapeutic target in human hepatocellular cancer. Mol. Cancer Ther.6, 1932–1941 (2007).
   PubMed Web of Science ®Google Scholar
• Gusarova GA, Wang IC, Major ML et al. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest.117, 99–111 (2007).
   PubMed Web of Science ®Google Scholar
• Ito H, Funahashi S, Yamauchi N et al. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin. Cancer Res.12, 3257–3264 (2006).
   PubMed Web of Science ®Google Scholar
• Fountoulakis M, Berndt P, Boelsteri UA et al. Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis21, 2148–2161 (2000).
   PubMed Web of Science ®Google Scholar
• Chevalier S, Macdonald N, Tonge R et al. Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumor necrosis factor a or the peroxisome proliferator nafenopin. Eur. J. Biochem.267, 4624–4634 (2000).
   PubMedGoogle Scholar
• Kim W, Lim SO, Kim J-S et al. Comparison of proteome between hepatitis B Virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin. Cancer Res.9, 5493–5500 (2003).
   PubMed Web of Science ®Google Scholar
• Lim SO, Park SJ, Kim W et al. Proteome analysis of hepatocellular carcinoma. Biochem. Biophys. Res. Commun.291, 1031–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Park KS, Kim H, Kim NG et al. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology35, 1459–1466 (2002).
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Kuramitsu Y, Takashima M et al. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics4, 2111–2116 (2004).
   PubMed Web of Science ®Google Scholar
• Packer NH, Pawlak A, Kett WC et al. Proteome analysis of glycoforms: a review of strategies for the microcharacterisation of glycoproteins separated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis18, 452–460 (1997).
   PubMed Web of Science ®Google Scholar
• Muller DR, Schindler P, Coulot M, Voshol H, van Oostrum J. Mass spectrometric characterization of stathmin isoforms separated by 2D PAGE. J. Mass Spectrom.34, 336–345 (1999).
   PubMed Web of Science ®Google Scholar
• Kim J, Kim SH, Lee SU et al. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis23, 4142–4156 (2002).
   PubMed Web of Science ®Google Scholar
• Paradis V, Degos F, Dargère D et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology41, 40–47 (2005).
   PubMed Web of Science ®Google Scholar
• Steel LF, Shumpert D, Trotter M et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics3, 601–609 (2003).
   PubMed Web of Science ®Google Scholar
• Naour FL, Brichory F, Misek DE et al. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol. Cell. Proteomics1, 197–203 (2002).
   PubMed Web of Science ®Google Scholar
• Takashima M, Kuramitsu Y, Yokoyama Y et al. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics6, 3894–3900 (2006).
   PubMed Web of Science ®Google Scholar
• Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal. Bioanal. Chem.382, 669–678 (2005).
   PubMed Web of Science ®Google Scholar
• Alban A, David SO, Bjorkesten L et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics3, 36–44 (2003).
   PubMed Web of Science ®Google Scholar
• Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis18, 2071–2077 (1997).
   PubMed Web of Science ®Google Scholar
• Zhou G, Li H, DeCamp D et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers Mol. Cell. Proteomics1, 117–123 (2002).
   PubMed Web of Science ®Google Scholar
• Lee IN, Chen CH, Sheu JC et al. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J. Proteome Res.4, 2062–2069 (2005).
   PubMed Web of Science ®Google Scholar
• Sun W, Xing B, Sun Y et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell. Proteomics6, 1798–1808 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou H, Liu Y, Chui J et al. Investigation on glycosylation patterns of proteins from human liver cancer cell lines based on the multiplexed proteomics technology. Arch. Biochem. Biophys.459, 70–78 (2007).
   PubMed Web of Science ®Google Scholar
• Zang L, Toy DP, Hancock WS, Sgroi DC, Karger BL. Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling. J. Proteome Res.3, 604–612 (2004).
   PubMed Web of Science ®Google Scholar
• Li C, Hong Y, Tan YX et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics3, 399–409 (2004).
   PubMed Web of Science ®Google Scholar
• Lin Z, Crockett DK, Jenson SD, Lim MS, Elenitoba-Johnson KS. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol. Cell. Proteomics3, 820–833 (2004).
   PubMed Web of Science ®Google Scholar
• Liu W, Guan M, Wu D et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur. Urol.,47, 456–462 (2005).
   PubMed Web of Science ®Google Scholar
• Woong-Shick A, Sung-Pil P, Su-Mi B et al. Identification of hemoglobin-a and -b subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci.,96, 197–201 (2005).
   PubMed Web of Science ®Google Scholar
• Malik G, Ward MD, Gupta SK et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res.11, 1073–1085 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell. Proteomics3, 355–366 (2004).
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics3, 367–378 (2004).
   PubMed Web of Science ®Google Scholar
• Laskin J, Futrell JH, Activation of large ions in FT-ICR mass spectrometry. Mass Spectrom. Rev.24, 135–167 (2005).
   Google Scholar
• Batista CV, del Pozo L, Zamudio FZ et al. Proteomics of the venom from the Amazonian scorpion Tityus cambridgei and the role of prolines on mass spectrometry analysis of toxins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.803, 55–66 (2004).
   PubMed Web of Science ®Google Scholar
• Clifton JG, Li X, Reutter W, Hixson DC, Josic D. Comparative proteomics of rat liver and Morris hepatoma 7777 plasma membranes. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.849, 293–301 (2007).
   PubMed Web of Science ®Google Scholar
• Paoletti AC, Zybailov B, Washburn MP. Principles and applications of multidimensional protein identification technology. Expert Rev. Proteomics1, 275–282 (2004).
   PubMed Web of Science ®Google Scholar
• Somiari RI, Somiari S, Russell S, Shriver CD. Proteomics of breast carcinoma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.815, 215–225 (2005).
   PubMed Web of Science ®Google Scholar
• Jue-Liang H, Shu-Hui C. Recent progress in quantitative proteomics using stable isotope labeling, multidimensional liquid chromatography and mass spectrometry Curr. Proteomics2, 287–302 (2005).
   PubMed Web of Science ®Google Scholar
• Evans G.A. Designer science and the ‘-omic’ revolution. Nature Biotechnol.18, 127 (2000).
   PubMed Web of Science ®Google Scholar
• Hocquette JE. Where are we in genomics? J. Physiol. Pharmacol.56, 37–70 (2005).
   PubMedGoogle Scholar
• Grivet J-P, Delort AM, Portais JC. NMR and microbiology: from physiology to metabolomics. Biochimie85, 823–840 (2003).
   PubMed Web of Science ®Google Scholar
• Buchholz A, Hurlebaus J, Wandrey C, Takors R. Metabolomics: quantification of intracellular metabolite dynamics. Biomol. Eng.19, 5–15 (2002).
   PubMedGoogle Scholar
• ter Kuile BH, Westerhoff HV. Transcriptome meets metabolome: hierarchical and metabolic regulation of the glycolytic pathway. FEBS Lett.500, 169–171 (2001).
   PubMed Web of Science ®Google Scholar
• Eakin RT, Morgan LO, Gregg CT, Matwiyoff NA. Carbon-13 nuclear magnetic resonance spectroscopy of living cells and their metabolism of a specifically labeled 13C substrate. FEBS Lett.28, 259–264 (1972).
   PubMed Web of Science ®Google Scholar
• Griffin JL. The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos. Trans. R Soc. Lond. B Biol. Sci.359, 857–871 (2004).
   PubMed Web of Science ®Google Scholar
• Griffiths JR, McSheehy PM, Robinson SP et al. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1β (HIF-1β): evidence of an anabolic role for the HIF-1 pathway. Cancer Res.62, 688–695 (2002).
   PubMed Web of Science ®Google Scholar
• Griffiths JR, Stubbs M. Opportunities for studying cancer by metabolomics: Preliminary observations on tumors deficient in hypoxia-inducible factor 1. Adv. Enzyme Regul.43, 67–76 (2003).
   PubMedGoogle Scholar
• Griffin JL, Kauppinen RA. Tumour metabolomics in animal models of human cancer. J. Proteome Res.6, 498–505 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao WD, Guan S, Zhou KR et al.in vivo detection of metabolic changes by 1H-MRS in the DEN-induced hepatocellular carcinoma in Wistar rat. J. Cancer Res. Clin. Oncol.131, 597–602 (2005).
   PubMed Web of Science ®Google Scholar
• Kusano M, Fukushima A, Kobayashi M et al. Application of a metabolomic method combining one-dimensional and two-dimensional gas chromatography-time-of-flight/mass spectrometry to metabolic phenotyping of natural variants in rice. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.855, 71–79 (2007).
   PubMed Web of Science ®Google Scholar
• Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal. Biochem.363, 185–195 (2007).
   PubMed Web of Science ®Google Scholar
• Borzio M, Fargion S, Borzio F et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J. Hepatol.39, 208–214 (2003).
   PubMed Web of Science ®Google Scholar
• Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin. Liver Dis.25,133–142 (2005).
   PubMed Web of Science ®Google Scholar
• Nam SW, Park JY, Ramasamy A et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology42, 809–818 (2005).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Chen Y, Wurmbach E et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology131, 1758–1767 (2006).
   PubMed Web of Science ®Google Scholar
• Boyault S, Rickman DS, de Reynies A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology45, 42–52 (2007).
   PubMed Web of Science ®Google Scholar
• Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology127, S51–S55 (2004).
   PubMed Web of Science ®Google Scholar
• Nishida N, Nishimura T, Nagasaka T et al. Extensive methylation is associated with β-catenin mutations in hepatocellular carcinoma, evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res.67, 4586–4594 (2007).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lee HS, Im JP et al. Association of transforming growth factor-β1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp. Mol. Med.35, 196–202 (2003).
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Yamada-Okabe H et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet361, 923–929 (2003).
   PubMed Web of Science ®Google Scholar
• Lee WC, Lee KH. Applications of affinity chromatography in proteomics. Anal. Biochem.324, 1–10 (2004).
   PubMed Web of Science ®Google Scholar
• Trakselis MA, Alley SC, Ishmael FT. Identification and mapping of protein–protein interactions by a combination of cross-linking, cleavage, and proteomics. Bioconjug. Chem.16, 741–750 (2005).
   PubMed Web of Science ®Google Scholar
• Hu S, Li Y, Liu G et al. A protein chip approach for high-throughput antigen identification and characterization. Proteomics7, 2151–2161 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu H, Bilgin M, Bangham R et al. Global analysis of protein activities using proteome chips. Science293, 2101–2105 (2001).
   PubMed Web of Science ®Google Scholar
• Kano M, Nishimura K, Ishikawa S et al. Expression imbalance map: a new visualization method for detection of mRNA expression imbalance regions. Physiol. Genomics13, 31–46 (2003).
   PubMed Web of Science ®Google Scholar
• Midorikawa Y, Tsutsumi S, Nishimura K et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res.64, 7263–7270 (2004).
   PubMed Web of Science ®Google Scholar
• Goesmann A, Linke B, Bartels D et al. BRIGEP – the BRIDGE-based genome–transcriptome–proteome browser. Nucl. Acid Res.33, W710–W716 (2005).
   PubMed Web of Science ®Google Scholar
• Drews O, Gorg A. DynaProt 2D: an advanced proteomic database for dynamic online access to proteomes and two-dimensional electrophoresis gels. Nucl. Acid Res.33, D583–D587 (2005).
   PubMedGoogle Scholar
• Liang RCMY, Neo JCH, Lo SL et al. Proteome database of hepatocellular carcinoma. J. Chromatogr. B771, 303–328 (2002).
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome Nucl. Acids Res.32, D277–D280 (2004).
   PubMed Web of Science ®Google Scholar
• Krummenacker M, Paley S, Mueller L, Yan T, Karp PD. Querying and computing with BioCyc databases. Bioinformatics21, 3454–3455 (2005).
   PubMed Web of Science ®Google Scholar
• Joshi-Tope G, Gillespie M, Vastrik I et al. Reactome: a knowledgebase of biological pathways Nucl. Acids Res.33, D428–D432 (2005).
   PubMed Web of Science ®Google Scholar
• Arita M. Additional paper: computational resources for metabolomics. Brief. Funct. Genomic. Proteomic.3, 84–93 (2004).
   PubMedGoogle Scholar
• Wishart DS, Tzur D, Knox C et al. HMDB: the Human Metabolome Database. Nucl. Acids Res.35, D521–D526 (2007).
   PubMed Web of Science ®Google Scholar
• Sauer S, Lange BM, Gobom J et al. Miniaturization in functional genomics and proteomics. Nat. Rev. Genet.6, 465–476 (2005).
   PubMed Web of Science ®Google Scholar
• Predki PF. Functional protein microarrays: ripe for discovery. Curr. Opin. Chem. Biol.8, 8–13 (2004).
   PubMed Web of Science ®Google Scholar
• Vautier G, Bomford AB, Portmann BC et al. p53 mutations in british patients with hepatocellular carcinoma, clustering in genetic hemochromatosis. Gastroenterology117, 154–160 (1999).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Legoix P, Bluteau O et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology120, 1763–1773 (2001).
   PubMed Web of Science ®Google Scholar
• Boix-Ferrero J, Pellin A, Blesa R, Adrados , Llombart-Bosch A. Absence of p53 gene mutations in hepatocarcinomas from a Mediterranean area of Spain. A study of 129 archival tumour samples. Virchows Arch.434, 497–501 (1999).
   PubMed Web of Science ®Google Scholar
• Hsu HC, Jeng YM, Mao TL et al. β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol.157, 763–770 (2000).
   PubMed Web of Science ®Google Scholar
• Legoix P, Bluteau O, Bayer J et al. β-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene18,4044–4046 (1999).
   PubMed Web of Science ®Google Scholar
• Ishizaki Y, Ikeda S, Fujimori M et al. Immunohistochemical analysis and mutational analyses of β-catenin, Axin family and APC genes in hepatocellular carcinomas. Int. J. Oncol.24, 1077–1083 (2004).
   PubMed Web of Science ®Google Scholar
• Yao YJ, Ping XL, Zhang H et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene18, 3181–3185 (1999).
   PubMed Web of Science ®Google Scholar
• Anzola M, Cuevas N, Lopez-Martinez M, Martinez de Pancorbo M, Burgos JJ. p16INK4A gene alterations are not a prognostic indicator for survival in patients with hepatocellular carcinoma undergoing curative hepatectomy. J. Gastroenterol. Hepatol.19, 397–405 (2004).
   PubMed Web of Science ®Google Scholar
• Qin LX, Tang ZY, Ma ZC et al. P53 immunohistochemical scoring, an independent prognostic marker for patients after hepatocellular carcinoma resection. World J. Gastroenterol.8, 459–463 (2002).
   PubMed Web of Science ®Google Scholar
• Fiorentino M, Altimari A, D’Errico A et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin. Cancer Res.6, 3966–3972 (2000).
   PubMed Web of Science ®Google Scholar
• Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y. Amplification of c-myc in hepatocellular carcinoma, correlation with clinicopathologic features, proliferative activity and p53 over expression. Oncology57, 157–163 (1999).
   PubMed Web of Science ®Google Scholar
• Morishita A, Masaki T, Yoshiji H et al. Reduced expression of cell cycle regulator p18INK4C in human hepatocellular carcinoma. Hepatology40, 677–686 (2004).
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin. Cancer Res.8, 3131–3136 (2002).
   PubMed Web of Science ®Google Scholar
• Jeng KS, Sheen IS, Wang YC et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma, a prospective study. World J. Gastroenterol.10, 643–648 (2004).
   PubMed Web of Science ®Google Scholar
• Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, a-catenin, β-catenin, and g-catenin proteins in hepatocellular carcinoma, relationships with tumor grade, clinicopathologic parameters, and patients’ survival. Hum. Pathol.31, 558–565 (2000).
   PubMed Web of Science ®Google Scholar
• Kishimoto K, Fujimoto J, Takeuchi M et al. Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J. Surg. Oncol.69, 119–124 (1998).
   PubMed Web of Science ®Google Scholar
• Kanmura S, Uto H, Kusumoto K et al. Early diagnostic potential for hepatocellular carcinoma using the SELDI Protein Chip system. Hepatology45, 948–956 (2007).
   PubMed Web of Science ®Google Scholar
• Melle C, Ernst G, Scheibner O et al. Identification of specific protein markers in microdissected hepatocellular carcinoma. J. Proteome Res.6, 306–315 (2007).
   PubMed Web of Science ®Google Scholar
• Gobel T, Vorderwulbecke S, Hauck K et al. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J. Gastroenterol.12, 7604–7612 (2006).
   PubMed Web of Science ®Google Scholar
• Blanc JF, Lalanne C, Plomion C et al. Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics5, 3778–3789 (2005).
   PubMed Web of Science ®Google Scholar
• Lee IN, Chen CH, Sheu JC et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics6, 2865–2873 (2006).
   PubMed Web of Science ®Google Scholar
• Yang ZF, Ho DW, Lam CT et al. Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res.65, 219–225 (2005).
   PubMed Web of Science ®Google Scholar
• Tannapfel A, Anhalt K, Häusermann P et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J. Pathol.201, 238–249 (2003).
   PubMed Web of Science ®Google Scholar